These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 18720480

  • 1. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
    Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS.
    Cancer; 2008 Oct 01; 113(7):1632-40. PubMed ID: 18720480
    [Abstract] [Full Text] [Related]

  • 2. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
    Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS.
    J Clin Oncol; 2007 Sep 01; 25(25):3802-7. PubMed ID: 17761969
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    González Cao M, Malvehy J, Martí R, Conill C, Sánchez M, Martín M, Carrera C, Herrero J, Gascón P, Mellado B, Castel T, Puig S.
    Melanoma Res; 2006 Feb 01; 16(1):59-64. PubMed ID: 16432457
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
    Masucci GV, Månsson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J.
    Melanoma Res; 2006 Aug 01; 16(4):357-63. PubMed ID: 16845332
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.
    Chemotherapy; 2009 Aug 01; 55(4):221-7. PubMed ID: 19451711
    [Abstract] [Full Text] [Related]

  • 8. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M, del Muro XG, Tres A, Crespo C, Valladares M, López JJ, Rifà J, Pérez X, Filipovich E, Germà-Lluch JR.
    Melanoma Res; 2006 Aug 01; 16(4):365-70. PubMed ID: 16845333
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.
    Cancer; 2006 Jun 01; 106(11):2445-51. PubMed ID: 16639739
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N, Middleton MR.
    J Clin Oncol; 2003 Jul 01; 21(13):2551-7. PubMed ID: 12829675
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C.
    Cancer Biother Radiopharm; 2000 Oct 01; 15(5):487-94. PubMed ID: 11155820
    [Abstract] [Full Text] [Related]

  • 14. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E, Hofmann-Wellenhof R, Pehamberger H, Forstinger Ch, Wolff K, Mischer P, Raml J, Fritsch P, Zelger B, Ratzinger G, Koller J, Lang A, Konrad K, Kindermann-Glebowski E, Seeber A, Steiner A, Fialla R, Pachinger W, Kos C, Klein G, Kehrer H, Kerl H, Ulmer H, Smolle J.
    Br J Dermatol; 2004 Jul 01; 151(1):91-8. PubMed ID: 15270876
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
    Fateh S, Schell TD, Gingrich R, Neves RI, Drabick JJ.
    Cancer Biol Ther; 2010 Dec 01; 10(11):1091-7. PubMed ID: 20930514
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
    Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.
    J Clin Oncol; 2003 Sep 01; 21(17):3351-6. PubMed ID: 12947072
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY.
    Cancer; 2004 Aug 01; 101(3):596-603. PubMed ID: 15274073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.